Table of Contents
Metal-Based Drugs
Volume 2008, Article ID 417897, 15 pages
http://dx.doi.org/10.1155/2008/417897
Review Article

Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism

1Department of Cytokinetics, Institute of Biophysics, Královopolská 135, Brno 612 65, Czech Republic
2Department of Vaccinology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno 621 00, Czech Republic

Received 30 May 2007; Revised 8 October 2007; Accepted 18 October 2007

Academic Editor: Rafael Moreno-Sanchez

Copyright © 2008 Alois Kozubík et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. J. Loehrer and L. H. Einhorn, “Drugs five years later. Cisplatin,” Annals of Internal Medicine, vol. 100, no. 5, 704 pages, 1984. View at Google Scholar
  2. V. Brabec and J. Kasparkova, “Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs,” Drug Resistance Updates, vol. 8, no. 3, 131 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  3. D. Wang and S. J. Lippard, “Cellular processing of platinum anticancer drugs,” Nature Reviews Drug Discovery, vol. 4, no. 4, 307 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  4. J. T. Hartmann and H.-P. Lipp, “Toxicity of platinum compounds,” Expert Opinion on Pharmacotherapy, vol. 4, no. 6, 889 pages, 2003. View at Publisher · View at Google Scholar · View at PubMed
  5. E. Cvitkovic and M. Bekradda, “Oxaliplatin: a new therapeutic option in colorectal cancer,” Seminars in Oncology, vol. 26, no. 6, 647 pages, 1999. View at Google Scholar
  6. P. J. O'Dwyer, J. P. Stevenson, and S. W. Johnson, “Clinical pharmacokinetics and administration of established platinum drugs,” Drugs, vol. 59, 19 pages, 2000. View at Google Scholar
  7. B. Lippert, Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, Wiley-VCH, Weinheim, Germany, 1999.
  8. T. Boulikas and M. Vougiouka, “Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review),” Oncology reports, vol. 11, no. 3, 559 pages, 2004. View at Google Scholar
  9. A. C. Buzaid and M. Atkins, “Practical guidelines for the management of biochemotherapy-related toxicity in melanoma,” Clinical Cancer Research, vol. 7, no. 9, 2611 pages, 2001. View at Google Scholar
  10. H. A. Norman, R. R. Butrum, E. Feldman et al., “The role of dietary supplements during cancer therapy,” Journal of Nutrition, vol. 133, no. 11, suppl. 1, 3794 pages, 2003. View at Google Scholar
  11. J. A. Plumb, W. Luo, and D. J. Kerr, “Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin,” British Journal of Cancer, vol. 67, no. 4, 728 pages, 1993. View at Google Scholar
  12. P. S. Sagar and U. N. Das, “Gamma-linolenic acid and eicosapentaeonic acid potentiate the cytotoxicity of anti-cancer drugs on human cervical carcinoma (HeLa) cells in vitro,” Medical Science Research, vol. 21, no. 12, 457 pages, 1993. View at Google Scholar
  13. H. Sasaki and M. Fukushima, “Prostaglandins in the treatment of cancer,” Anti-Cancer Drugs, vol. 5, no. 2, 131 pages, 1994. View at Google Scholar
  14. T. S. W. Sam, M. P. Ngan, D. Riendeau, A. Robichaud, and J. A. Rudd, “Action of cyclooxygenase inhibitors and a leukotriene biosynthesis inhibitor on cisplatin-induced acute and delayed emesis in the ferret,” Journal of Pharmacological Sciences, vol. 103, no. 2, 189 pages, 2007. View at Publisher · View at Google Scholar
  15. F. Žák, J. Turánek, A. Kroutil et al., “Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines,” Journal of Medicinal Chemistry, vol. 47, no. 3, 761 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  16. B. Rosenberg, L. Vancamp, and T. Krigas, “Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode,” Nature, vol. 205, 698 pages, 1965. View at Google Scholar
  17. C. M. Giandomenico, M. J. Abrams, B. A. Murrer et al., “Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entrée orally-active platinum(IV) antitumor agents,” Inorganic Chemistry, vol. 34, no. 5, 1015 pages, 1995. View at Publisher · View at Google Scholar
  18. E. G. Talman, Y. Kidani, L. Mohrmann, and J. Reedijk, “Can Pt(IV)-amine complexes act as “prodrugs”?,” Inorganica Chimica Acta, vol. 283, no. 1, 251 pages, 1998. View at Publisher · View at Google Scholar
  19. E. Wong and C. M. Giandornenico, “Current status of platinum-based antitumor drugs,” Chemical Reviews, vol. 99, no. 9, 2451 pages, 1999. View at Publisher · View at Google Scholar
  20. J. Cermanova, J. Chladek, P. Soval et al., “Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]-amminedichloroplatinum [IV]) in pigs,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 26, no. 9, 679 pages, 2004. View at Publisher · View at Google Scholar
  21. P. Sova, A. Mistr, A. Kroutil, F. Zak, P. Pouckova, and M. Zadinova, “Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12,” Anti-Cancer Drugs, vol. 16, no. 6, 653 pages, 2005. View at Publisher · View at Google Scholar
  22. A. Kozubík, V. Horváth, L. Švihálková-Šindlerová et al., “High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro,” Biochemical Pharmacology, vol. 69, no. 3, 373 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  23. J. Turánek, A. Kašná, D. Záluská et al., “New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes,” Anti-Cancer Drugs, vol. 15, no. 5, 537 pages, 2004. View at Google Scholar
  24. L. Procházka, J. Turánek, R. Tesařík et al., “Apoptosis and inhibition of gap-junctional intercellular communication induced by LA-12, a novel hydrophobic platinum(IV) complex,” Archives of Biochemistry and Biophysics, vol. 462, no. 1, 54 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  25. V. Horváth, O. Blanářová, L. Švihálková-Šindlerová et al., “Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells,” Gynecologic Oncology, vol. 102, no. 1, 32 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  26. J. Kašpárková, O. Nováková, O. Vrána, F. Intini, G. Natile, and V. Brabec, “Molecular aspects of antitumor effects of a new platinum(IV) drug,” Molecular Pharmacology, vol. 70, no. 5, 1708 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  27. S. M. Cohen and S. J. Lippard, “Cisplatin: from DNA damage to cancer chemotherapy,” Progress in Nucleic Acid Research and Molecular Biology, vol. 67, 93 pages, 2001. View at Google Scholar
  28. Z. H. Siddik, “Cisplatin: mode of cytotoxic action and molecular basis of resistance,” Oncogene, vol. 22, no. 47, 7265 pages, 2003. View at Google Scholar
  29. E. R. Jamieson and S. J. Lippard, “Structure, recognition, and processing of cisplatin-DNA adducts,” Chemical Reviews, vol. 99, no. 9, 2467 pages, 1999. View at Publisher · View at Google Scholar
  30. J. Brouwer, P. Van De Putte, A. M. Fichtinger-Schepman, and J. Reedijk, “Base-pair substitution hotspots in GAG and GCG nucleotide sequences in Escherichia coli K-12 induced by cis-diamminedichloroplatinum (II),” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 11, 7010 pages, 1981. View at Publisher · View at Google Scholar
  31. M. A. Fuertesa, J. Castillab, C. Alonsoa, and J. M. Perez, “Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways,” Current Medicinal Chemistry, vol. 10, no. 3, 257 pages, 2003. View at Google Scholar
  32. R. P. Perez, “Cellular and molecular determinants of cisplatin resistance,” European Journal of Cancer, vol. 34, no. 10, 1535 pages, 1998. View at Publisher · View at Google Scholar
  33. N. Moeller, B. S. Kangarloo, I. Puscasu, C. Mock, B. Krebs, and J. E. A. Wolff, “Rational design of platinum chemotherapeutic drugs: hydrophobicity increases cytotoxicity,” Anticancer Research, vol. 20, no. 6 B, 4435 pages, 2000. View at Google Scholar
  34. M. Kool, M. De Haas, G. L. Scheffer et al., “Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines,” Cancer Research, vol. 57, no. 16, 3537 pages, 1997. View at Google Scholar
  35. K. V. Ferry, T. C. Hamilton, and S. W. Johnson, “Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF,” Biochemical Pharmacology, vol. 60, no. 9, 1305 pages, 2000. View at Publisher · View at Google Scholar
  36. L. R. Kelland, “Structure-activity relationship within di- and trinuclear platinum phase I clinical agents,” in Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, B Lippert, Ed., p. 497, Wiley-VCH, Weinheim, Germany, 1999. View at Google Scholar
  37. A. B. Hendrich and K. Michalak, “Lipids as a target for drugs modulating multidrug resistance of cancer cells,” Current Drug Targets, vol. 4, no. 1, 23 pages, 2003. View at Publisher · View at Google Scholar
  38. V. Gouaze-Andersson and M. C. Cabot, “Glycosphingolipids and drug resistance,” Biochimica et Biophysica Acta, vol. 1758, no. 12, 2096 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. J. W. J. Hinrichs, K. Klappe, and J. W. Kok, “Rafts as missing link between multidrug resistance and sphingolipid metabolism,” Journal of Membrane Biology, vol. 203, no. 2, 57 pages, 2005. View at Publisher · View at Google Scholar
  40. V. Cepeda, M. A. Fuertes, J. Castilla, C. Alonso, C. Quevedo, and J. M. Pérez, “Biochemical mechanisms of cisplatin cytotoxicity,” Anti-Cancer Agents in Medicinal Chemistry, vol. 7, no. 1, 3 pages, 2007. View at Google Scholar
  41. S. Tardito, O. Bussolati, F. Gaccioli et al., “Non-apoptotic programmed cell death induced by a copper(II) complex in human fibrosarcoma cells,” Histochemistry and Cell Biology, vol. 126, no. 4, 473 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  42. A. Suliman, A. Lam, R. Datta, and R. K. Srivastava, “Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways,” Oncogene, vol. 20, no. 17, 2122 pages, 2001. View at Publisher · View at Google Scholar · View at PubMed
  43. S. Rodriguez-Nieto and B. Zhivotovsky, “Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment,” Current Pharmaceutical Design, vol. 12, no. 34, 4411 pages, 2006. View at Publisher · View at Google Scholar
  44. B. Zhivotovsky and S. Orrenius, “Caspase-2 function in response to DNA damage,” Biochemical and Biophysical Research Communications, vol. 331, no. 3, 859 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  45. K.-M. Debatin and P. H. Krammer, “Death receptors in chemotherapy and cancer,” Oncogene, vol. 23, no. 16, 2950 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  46. A. Vaculová, J. Hofmanová, L. Anděra, and A. Kozubík, “TRAIL and docosahexaenoic acid cooperate to induce HT-29 colon cancer cell death,” Cancer Letters, vol. 229, no. 1, 43 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  47. A. Vaculová, J. Hofmanová, K. Souček, and A. Kozubík, “Different modulation of TRAIL-induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells,” FEBS Letters, vol. 580, no. 28–29, 6565 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  48. S. Shankar, X. Chen, and R. K. Srivastava, “Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo,” Prostate, vol. 62, no. 2, 165 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  49. O. Micheau, E. Solary, A. Hammann, F. Martin, and M.-T. Dimanche-Boitrel, “Sensitization of cancer cells treated with cytotoxic drugs to fas- mediated cytotoxicity,” Journal of the National Cancer Institute, vol. 89, no. 11, 783 pages, 1997. View at Publisher · View at Google Scholar
  50. D. Delmas, C. Rébé, O. Micheau et al., “Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells,” Oncogene, vol. 23, no. 55, 8979 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  51. S. Lacour, A. Hammann, A. Wotawa, L. Corcos, E. Solary, and M.-T. Dimanche-Boitrel, “Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis,” Cancer Research, vol. 61, no. 4, 1645 pages, 2001. View at Google Scholar
  52. K. Shimada, S. Matsuyoshi, M. Nakamura, E. Ishida, M. Kishi, and N. Konishi, “Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis,” Carcinogenesis, vol. 25, no. 7, 1089 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  53. H. Kinoshita, H. Yoshikawa, K. Shiiki, Y. Hamada, Y. Nakajima, and K. Tasaka, “Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression,” International Journal of Cancer, vol. 88, no. 6, 986 pages, 2000. View at Publisher · View at Google Scholar
  54. W. Liu, E. Bodle, J. Y. Che, M. Gao, G. D. Rosen, and V. C. Broaddus, “Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines,” American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 1, 111 pages, 2001. View at Google Scholar
  55. W. S. Tsai, W.-S. Yeow, A. Chua et al., “Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin,” Molecular Cancer Therapeutics, vol. 5, no. 12, 2977 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  56. D. M. Nguyen, W.-S. Yeow, M. Firdos Ziauddin et al., “The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death,” Cancer Journal, vol. 12, no. 4, 257 pages, 2006. View at Google Scholar
  57. P. Wang, J. H. Song, D. K. Song, J. Zhang, and C. Hao, “Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis,” Cellular Signalling, vol. 18, no. 9, 1528 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  58. M. Rosen, M. Figliomeni, and H. Simpkins, “The interaction of platinum antitumour drugs with mouse liver mitochondria,” International Journal of Experimental Pathology, vol. 73, no. 1, 61 pages, 1992. View at Google Scholar
  59. L. Zhang, A. J. L. Cooper, B. F. Krasnikov et al., “Cisplatin-induced toxicity is associated with platinum deposition in mouse kidney mitochondria in vivo and with selective inactivation of the α-ketoglutarate dehydrogenase complex in LLC-PK1 cells,” Biochemistry, vol. 45, no. 29, 8959 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  60. A.-K. Souid, K. A. Tacka, K. A. Galvan, and H. S. Penefsky, “Immediate effects of anticancer drugs on mitochondrial oxygen consumption,” Biochemical Pharmacology, vol. 66, no. 6, 977 pages, 2003. View at Publisher · View at Google Scholar
  61. R. M. Evans and H. Simpkins, “Cisplatin induced intermediate filament reorganization and altered mitochondrial function in 3T3 cells and drug-sensitive and -resistant walker 256 cells,” Experimental Cell Research, vol. 245, no. 1, 69 pages, 1998. View at Publisher · View at Google Scholar · View at PubMed
  62. Z. Yang, L. M. Schumaker, M. J. Egorin, E. G. Zuhowski, Z. Guo, and K. J. Cullen, “Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis,” Clinical Cancer Research, vol. 12, no. 19, 5817 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  63. Y. Dong, S. J. Berners-Price, D. R. Thorburn et al., “Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy,” Biochemical Pharmacology, vol. 53, no. 11, 1673 pages, 1997. View at Publisher · View at Google Scholar
  64. W. Qian, M. Nishikawa, A. M. Haque et al., “Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death,” American Journal of Physiology—Cell Physiology, vol. 289, no. 6, C1466 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  65. S. Isonishi, M. Saitou, M. Yasuda, and T. Tanaka, “Mitochondria in platinum resistant cells,” Human Cell, vol. 14, no. 3, 203 pages, 2001. View at Google Scholar
  66. K. Endo, S. Kohnoe, E. Tsujita et al., “Modulation of anti-apoptosis by endogenous IAP expression in MKN45 human gastric cancer cells,” Anticancer Research, vol. 25, no. 4, 2713 pages, 2005. View at Google Scholar
  67. H. J. Cho, J. K. Kim, K. D. Kim et al., “Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells,” Cancer Letters, vol. 237, no. 1, 56 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  68. D. Arango, A. J. Wilson, Q. Shi et al., “Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells,” British Journal of Cancer, vol. 91, no. 11, 1931 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  69. T. Mueller, W. Voigt, H. Simon et al., “Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer,” Cancer Research, vol. 63, no. 2, 513 pages, 2003. View at Google Scholar
  70. Z. Ding, X. Yang, A. Pater, and S.-C. Tang, “Resistance to apoptosis is correlated with the reduced caspase-3 activation and enhanced expression of antiapoptotic proteins in human cervical multidrug-resistant cells,” Biochemical and Biophysical Research Communications, vol. 270, no. 2, 415 pages, 2000. View at Publisher · View at Google Scholar · View at PubMed
  71. R. Seth, C. Yang, V. Kaushal, S. V. Shah, and G. P. Kaushal, “p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury,” Journal of Biological Chemistry, vol. 280, no. 35, 31230 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  72. H. D. C. Francescato, R. S. Costa, C. Scavone, and T. M. Coimbra, “Parthenolide reduces cisplatin-induced renal damage,” Toxicology, vol. 230, no. 1, 64 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  73. T. Drewa, A. Woźniak, G. Drewa et al., “Effect of novel platinum complexes on survival rate of B16 and Cl S91 melanoma cells and oxidation stress in vitro,” Medical Science Monitor, vol. 7, no. 4, 680 pages, 2001. View at Google Scholar
  74. S. Sentürker, R. Tschirret-Guth, J. Morrow, R. Levine, and E. Shacter, “Induction of apoptosis by chemotherapeutic drugs without generation of reactive oxygen species,” Archives of Biochemistry and Biophysics, vol. 397, no. 2, 262 pages, 2002. View at Publisher · View at Google Scholar · View at PubMed
  75. G. N. Kaludjerović, D. Miljković, M. Momcilović et al., “Novel platinum(IV) complexes induce rapid tumor cell death in vitro,” International Journal of Cancer, vol. 116, no. 3, 479 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  76. K. Husain, C. Whitworth, and L. P. Rybak, “Time response of carboplatin-induced nephrotoxicity in rats,” Pharmacological Research, vol. 50, no. 3, 291 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  77. B. Olas, B. Wachowicz, I. Majsterek, and J. Blasiak, “Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and lymphocytes,” Anti-Cancer Drugs, vol. 16, no. 6, 659 pages, 2005. View at Publisher · View at Google Scholar
  78. H. W. Pogrebniak, T. W. Prewitt, W. A. Matthews, and H. I. Pass, “Tumor necrosis factor-α alters response of lung cancer cells to oxidative stress,” Journal of Thoracic and Cardiovascular Surgery, vol. 102, no. 6, 904 pages, 1991. View at Google Scholar
  79. P. V. Escribá, “Membrane-lipid therapy: a new approach in molecular medicine,” Trends in Molecular Medicine, vol. 12, no. 1, 34 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  80. M. D. Brown, C. A. Hart, E. Gazi, S. Bagley, and N. W. Clarke, “Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs,” British Journal of Cancer, vol. 94, no. 6, 842 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  81. H. Bartsch, J. Nair, and R. W. Owen, “Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers,” Carcinogenesis, vol. 20, no. 12, 2209 pages, 1999. View at Publisher · View at Google Scholar
  82. D. P. Rose and J. M. Connolly, “Omega-3 fatty acids as cancer chemopreventive agents,” Pharmacology and Therapeutics, vol. 83, no. 3, 217 pages, 1999. View at Publisher · View at Google Scholar
  83. L. A. Davidson, D. V. Nguyen, R. M. Hokanson et al., “Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat,” Cancer Research, vol. 64, no. 18, 6797 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  84. S. C. Larsson, M. Kumlin, M. Ingelman-Sundberg, and A. Wolk, “Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms,” American Journal of Clinical Nutrition, vol. 79, no. 6, 935 pages, 2004. View at Google Scholar
  85. W. E. Hardman, C. P. Avula, G. Fernandes, and I. L. Cameron, “Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts,” Clinical Cancer Research, vol. 7, no. 7, 2041 pages, 2001. View at Google Scholar
  86. A. Jordan and J. Stein, “Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2,” European Journal of Nutrition, vol. 42, no. 6, 324 pages, 2003. View at Publisher · View at Google Scholar · View at PubMed
  87. P. Bougnoux, E. Germain, V. Chajés et al., “Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma,” British Journal of Cancer, vol. 79, no. 11-12, 1765 pages, 1999. View at Google Scholar
  88. H. Timmer-Bosscha, G. A. P. Hospers, C. Meijer et al., “Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line,” Journal of the National Cancer Institute, vol. 81, no. 14, 1069 pages, 1989. View at Publisher · View at Google Scholar
  89. D. Yam, A. Peled, and M. Shinitzky, “Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin,” Cancer Chemotherapy and Pharmacology, vol. 47, no. 1, 34 pages, 2001. View at Publisher · View at Google Scholar
  90. D. H. Jho, S. M. Cole, E. M. Lee, and N. J. Espat, “Role of omega-3 fatty acid supplementation in inflammation and malignancy,” Integrative Cancer Therapies, vol. 3, no. 2, 98 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  91. P. V. Escriba, A. V. Ferrer-Montiel, J. A. Ferragut, and J. M. Gonzalez-Ros, “Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena,” Biochemistry, vol. 29, no. 31, 7275 pages, 1990. View at Publisher · View at Google Scholar
  92. N. Mikirova, H. D. Riordan, J. A. Jackson, K. Wong, J. R. Miranda-Massari, and M. J. Gonzalez, “Erythrocyte membrane fatty acid composition in cancer patients,” Puerto Rico Health Sciences Journal, vol. 23, no. 2, 107 pages, 2004. View at Google Scholar
  93. X.-J. Liang, J.-J. Yin, J.-W. Zhou et al., “Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells,” Experimental Cell Research, vol. 293, no. 2, 283 pages, 2004. View at Publisher · View at Google Scholar
  94. S. C. Mann, P. A. Andrews, and S. B. Howell, “Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells,” Anticancer Research, vol. 8, no. 6, 1211 pages, 1988. View at Google Scholar
  95. Q. Liu, Y. Qu, R. Van Antwerpen, and N. Farrell, “Mechanism of the membrane interaction of polynuclear platinum anticancer agents. Implications for cellular uptake,” Biochemistry, vol. 45, no. 13, 4248 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  96. G. Speelmans, R. W. H. M. Staffhorst, K. Versluis, J. Reedijk, and B. De Kruijff, “Cisplatin complexes with phosphatidylserine in membranes,” Biochemistry, vol. 36, no. 34, 10545 pages, 1997. View at Publisher · View at Google Scholar · View at PubMed
  97. U. Das, “A radical approach to cancer,” Medical Science Monitor, vol. 8, no. 4, RA79 pages, 2002. View at Google Scholar
  98. S. N. Meydani, “Effect of (n-3) polyunsaturated fatty acids on cytokine production and their biologic function,” Nutrition, vol. 12, no. 1, suppl., 8 pages, 1996. View at Google Scholar
  99. I. L. Rudolph, D. S. Kelley, K. C. Klasing, and K. L. Erickson, “Regulation of cellular differentiation and apoptosis by fatty acids and their metabolites,” Nutrition Research, vol. 21, no. 1-2, 381 pages, 2001. View at Publisher · View at Google Scholar
  100. D. A. Los and N. Murata, “Membrane fluidity and its roles in the perception of environmental signals,” Biochimica et Biophysica Acta, vol. 1666, no. 1-2, 142 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  101. S. Lacour, A. Hammann, S. Grazide et al., “Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells,” Cancer Research, vol. 64, no. 10, 3593 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  102. W. Stillwell and S. R. Wassall, “Docosahexaenoic acid: membrane properties of a unique fatty acid,” Chemistry and Physics of Lipids, vol. 126, no. 1, 1 pages, 2003. View at Publisher · View at Google Scholar
  103. J. Pohl, A. Ring, R. Ehehalt, T. Herrmann, and W. Stremmel, “New concepts of cellular fatty acid uptake: role of fatty acid transport proteins and of caveolae,” Proceedings of the Nutrition Society, vol. 63, no. 2, 259 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  104. M. Krönke, “Biophysics of ceramide signaling: interaction with proteins and phase transition of membranes,” Chemistry and Physics of Lipids, vol. 101, no. 1, 109 pages, 1999. View at Publisher · View at Google Scholar
  105. P. D. Schley, D. N. Brindley, and C. J. Field, “(n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells,” Journal of Nutrition, vol. 137, no. 3, 548 pages, 2007. View at Google Scholar
  106. J. C. Fernández-Checa, “Redox regulation and signaling lipids in mitochondrial apoptosis,” Biochemical and Biophysical Research Communications, vol. 304, no. 3, 471 pages, 2003. View at Publisher · View at Google Scholar
  107. V. Hirunpanich, J. Katagi, B. Sethabouppha, and H. Sato, “Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats,” Drug Metabolism and Disposition, vol. 34, no. 2, 305 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  108. Q. Y. Liu and B. K. H. Tan, “Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines,” Life Sciences, vol. 67, no. 10, 1207 pages, 2000. View at Publisher · View at Google Scholar
  109. A. N. Abulrob, M. Mason, R. Bryce, and M. Gumbleton, “The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance,” Journal of Drug Targeting, vol. 8, no. 4, 247 pages, 2000. View at Google Scholar
  110. M. Di Paola and M. Lorusso, “Interaction of free fatty acids with mitochondria: coupling, uncoupling and permeability transition,” Biochimica et Biophysica Acta, vol. 1757, no. 9-10, 1330 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  111. V. E. Kagan, G. G. Borisenko, Y. Y. Tyurina et al., “Oxidative lipidomics of apoptosis: redox catalytic interactions of cytochrome c with cardiolipin and phosphatidylserine,” Free Radical Biology and Medicine, vol. 37, no. 12, 1963 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  112. Y. Ng, R. Barhoumi, R. B. Tjalkens et al., “The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes,” Carcinogenesis, vol. 26, no. 11, 1914 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  113. M. Degli Esposti, G. Ferry, P. Masdehors, J. A. Boutin, J. A. Hickman, and C. Dive, “Post-translational modification of Bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3,” Journal of Biological Chemistry, vol. 278, no. 18, 15749 pages, 2003. View at Publisher · View at Google Scholar · View at PubMed
  114. C. Maziére, M.-A. Conte, J. Degonville, D. Ali, and J.-C. Maziére, “Cellular enrichment with polyunsaturated fatty acids induces an oxidative stress and activates the transcription factors AP1 and NFκB,” Biochemical and Biophysical Research Communications, vol. 265, no. 1, 116 pages, 1999. View at Publisher · View at Google Scholar · View at PubMed
  115. J. Hofmanová, A. Vaculová, and A. Kozubík, “Polyunsaturated fatty acids sensitize human colon adenocarcinoma HT-29 cells to death receptor-mediated apoptosis,” Cancer Letters, vol. 218, no. 1, 33 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  116. G. Muzio, R. A. Salvo, A. Trombetta et al., “Dose-dependent inhibition of cell proliferation induced by lipid peroxidation products in rat hepatoma cells after enrichment with arachidonic acid,” Lipids, vol. 34, no. 7, 705 pages, 1999. View at Publisher · View at Google Scholar
  117. U. N. Das, Y. S. Huang, M. E. Begin, G. Ells, and D. F. Horrobin, “Uptake and distribution of cis-unsaturated fatty acids and their effect on free radical generation in normal and tumor cells in vitro,” Free Radical Biology & Medicine, vol. 3, no. 1, 9 pages, 1987. View at Publisher · View at Google Scholar
  118. L. Fialkow, Y. Wang, and G. P. Downey, “Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function,” Free Radical Biology and Medicine, vol. 42, no. 2, 153 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  119. Y. Kabe, K. Ando, S. Hirao, M. Yoshida, and H. Handa, “Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus,” Antioxidants and Redox Signaling, vol. 7, no. 3-4, 395 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  120. H. Sampath and J. M. Ntambi, “Polyunsaturated fatty acid regulation of genes of lipid metabolism,” Annual Review of Nutrition, vol. 25, 317 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  121. S. C. Mills, A. C. Windsor, and S. C. Knight, “The potential interactions between polyunsaturated fatty acids and colonic inflammatory processes,” Clinical and Experimental Immunology, vol. 142, no. 2, 216 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  122. A. N. K. Yusufi, J. Cheng, M. A. Thompson et al., “Differential effects of low-dose docosahexaenoic acid and eicosapentaenoic acid on the regulation of mitogenic signaling pathways in mesangial cells,” Journal of Laboratory and Clinical Medicine, vol. 141, no. 5, 318 pages, 2003. View at Publisher · View at Google Scholar · View at PubMed
  123. W.-L. Yang and H. Frucht, “Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells,” Carcinogenesis, vol. 22, no. 9, 1379 pages, 2001. View at Publisher · View at Google Scholar
  124. C. P. Diggle, “In vitro studies on the relationship between polyunsaturated fatty acids and cancer: tumour or tissue specific effects?,” Progress in Lipid Research, vol. 41, no. 3, 240 pages, 2002. View at Publisher · View at Google Scholar
  125. A. P. Simopoulos, “The importance of the ratio of omega-6/omega-3 essential fatty acids,” Biomedicine and Pharmacotherapy, vol. 56, no. 8, 365 pages, 2002. View at Publisher · View at Google Scholar
  126. H. Toriyama-Baba, M. Iigo, M. Asamoto et al., “Organotropic chemopreventive effects of n-3 unsaturated fatty acids in a rat multi-organ carcinogenesis model,” Japanese Journal of Cancer Research, vol. 92, no. 11, 1175 pages, 2001. View at Google Scholar
  127. R. Dentin, F. Benhamed, J.-P. Pégorier et al., “Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation,” Journal of Clinical Investigation, vol. 115, no. 10, 2843 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  128. R. Geney, J. Chen, and I. Ojima, “Recent advances in the new generation taxane anticancer agents,” Medicinal chemistry, vol. 1, no. 2, 125 pages, 2005. View at Google Scholar
  129. M. O. Bradley, N. L. Webb, F. H. Anthony et al., “Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel,” Clinical Cancer Research, vol. 7, no. 10, 3229 pages, 2001. View at Google Scholar
  130. L. Kuznetsova, J. Chen, L. Sun et al., “Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 4, 974 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  131. A. Nagayasu, K. Uchiyama, and H. Kiwada, “The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs,” Advanced Drug Delivery Reviews, vol. 40, no. 1-2, 75 pages, 1999. View at Publisher · View at Google Scholar
  132. P. K. Working, M. S. Newman, T. Sullivan et al., “Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys,” Toxicological Sciences, vol. 46, no. 1, 155 pages, 1998. View at Publisher · View at Google Scholar · View at PubMed
  133. T. Boulikas, G. P. Stathopoulos, N. Volakakis, and M. Vougiouka, “Systemic lipoplatin infusion results in preferential tumor uptake in human studies,” Anticancer Research, vol. 25, no. 4, 3031 pages, 2005. View at Google Scholar
  134. G. P. Stathopoulos, T. Boulikas, A. Kourvetaris, and J. Stathopoulos, “Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study,” Anticancer Research, vol. 26, no. 2 B, 1489 pages, 2006. View at Google Scholar
  135. T. Dragovich, D. Mendelson, S. Kurtin, K. Richardson, D. Von Hoff, and A. Hoos, “A phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer,” Cancer Chemotherapy and Pharmacology, vol. 58, no. 6, 759 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  136. M. Mesnil, S. Crespin, J.-L. Avanzo, and M.-L. Zaidan-Dagli, “Defective gap junctional intercellular communication in the carcinogenic process,” Biochimica et Biophysica Acta, vol. 1719, no. 1-2, 125 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  137. J. E. Trosko and C.-C. Chang, “Mechanism of up-regulated gap junctional intercellular communication during chemoprevention and chemotherapy of cancer,” Mutation Research, vol. 480-481, 219 pages, 2001. View at Publisher · View at Google Scholar
  138. D. Giessmann, C. Theiss, W. Breipohl, and K. Meller, “Decreased gap junctional communication in neurobiotin microinjected lens epithelial cells after taxol treatment,” Anatomy and Embryology, vol. 209, no. 5, 391 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  139. K. Abdelmohsen, C. von Montfort, D. Stuhlmann et al., “Doxorubicin induces EGF receptor-dependent downregulation of gap junctional intercellular communication in rat liver epithelial cells,” Biological Chemistry, vol. 386, no. 3, 217 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  140. W. Zhao, Z. X. Lin, and Z. Q. Zhang, “Cisplatin-induced premature senescence with concomitant reduction of gap junctions in human fibroblasts,” Cell Research, vol. 14, no. 1, 60 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  141. C. A. Presley, A. W. Lee, B. Kastl et al., “Bone marrow connexin-43 expression is critical for hematopoietic regeneration after chemotherapy,” Cell Communication and Adhesion, vol. 12, no. 5-6, 307 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  142. G. D. Carystinos, M.A. Alaoui-Jamali, J. Phipps, L. Yen, and G. Batist, “Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all-trans-retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells,” Cancer Chemotherapy and Pharmacology, vol. 47, no. 2, 126 pages, 2001. View at Publisher · View at Google Scholar
  143. M. Tanaka and H. B. Grossman, “Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells,” Oncology Reports, vol. 11, no. 2, 537 pages, 2004. View at Google Scholar
  144. C. R. Toler, D. D. Taylor, and C. Gercel-Taylor, “Loss of communication in ovarian cancer,” American Journal of Obstetrics and Gynecology, vol. 194, no. 5, e27 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  145. K. Kawamura, R. Bahar, H. Namba et al., “Bystander effect in uracil phosphoribosyltransferase/5-fluorouracil-mediated suicide gene therapy is correlated with the level of intercellular communication,” International Journal of Oncology, vol. 18, no. 1, 117 pages, 2001. View at Google Scholar
  146. G. O. Edwards, S. W. Botchway, G. Hirst, C. W. Wharton, J. K. Chipman, and R. A. Meldrum, “Gap junction communication dynamics and bystander effects from ultrasoft X-rays,” British Journal of Cancer, vol. 90, no. 7, 1450 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  147. R. Jensen and P. M. Glazer, “Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 16, 6134 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed
  148. F. Bunz, “Cell death and cancer therapy,” Current Opinion in Pharmacology, vol. 1, no. 4, 337 pages, 2001. View at Publisher · View at Google Scholar
  149. R. P. Wernyj and P. J. Morin, “Molecular mechanisms of platinum resistance: still searching for the Achilles' heel,” Drug Resistance Updates, vol. 7, no. 4-5, 227 pages, 2004. View at Publisher · View at Google Scholar · View at PubMed